Acute liver failure in Cuban children

César E Silverio1, Chleo Y Smithen-Romany, Norma I Hondal

  • 1William Soler University Children's Hospital (HPUWS), Havana, Cuba. mcastell@infomed.sld.cu.

MEDICC Review
|March 2, 2015
PubMed

Insights

Acute liver failure in Cuban children is often caused by infection, particularly cytomegalovirus in infants. Severe hepatic encephalopathy significantly increases mortality risk, highlighting the need for further research into local causes.

Area of Science:

  • Pediatric Hepatology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Acute liver failure (ALF) is a rare and critical pediatric emergency with significant prognostic and therapeutic challenges.
  • Limited data exists on ALF in pediatric populations in Cuba, necessitating local research.

Purpose of the Study:

  • To describe the clinical features of pediatric patients diagnosed with acute liver failure in Cuba.
  • To identify the main etiologies and outcomes of ALF in Cuban children.

Main Methods:

  • A case series study was conducted from 2005 to 2011 at a national referral center in Havana.
  • Data collected included age, etiology, hepatic encephalopathy grade, blood chemistry, and clinical outcomes.
  • Statistical analyses included contingency tables, Mann-Whitney U test, and calculation of case fatality and relative risk.

Main Results:

  • The study included 31 children (14 boys, 17 girls) with a median age of 24 months.
  • Infections, primarily nonhepatotropic viruses like cytomegalovirus in infants, were the most common etiology (61.3%).
  • Case fatality was 41.9%; outcomes were significantly associated with hepatic encephalopathy grade (p <0.01) and lower cholesterol levels (p <0.01).

Conclusions:

  • Clinical characteristics of ALF in Cuban children resemble those in developed countries.
  • Nonhepatotropic viruses, especially cytomegalovirus, are the primary cause of ALF in Cuban infants, warranting further epidemiological investigation.
  • Identifying local determinants of ALF in this population is crucial for future interventions.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
263
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
358
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.4K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
362
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
359
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391